Spine BioPharma
Business Services · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
505 Park Ave Fl 14, New York, New York, ...Phone Number
(212) 583-9700Website
www.spinebiopharma.comRevenue
$13.9 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Spine BioPharma
Spine BioPharma is a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease. The company was established in 2015 and is headquartered out of New York City, NY.Explore more
Spine BioPharma Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spine BioPharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Spine BioPharma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Spine BioPharma
Click to see if Spine BioPharma had a recent Job posting/layoffs
Check if Spine BioPharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Spine BioPharma recently announced quarterly report
Product Launch: Get notified when Spine BioPharma launches new products
Funding: Get notified immidiatlly once Spine BioPharma has new funding data
Check out if Spine BioPharma is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Spine BioPharma
Compare insights from companies similar to Spine BioPharma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Spine BioPharma is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Spine BioPharma is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Spine BioPharma.
Spine BioPharma financials insights
Gather financial insights about Spine BioPharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$5M
Corporate Investment
$3M
2022
Series B
$13M
2026
Stock/Share Issuance
$385K
Spine BioPharma Tech Stack
A closer look at the technologies used by Spine BioPharma
Most Recent Scoops
Funding
Funding
Funding
Funding
Funding
Spine BioPharma News & Media
Spine BioPharma, Inc. to Present at Biotech Showcase 2025
NEW YORK--(BUSINESS WIRE)--Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced that Chief Executive Officer Marc Viscogliosi will present a corporate overview and update at Biotech Showcase 2025, taking place in San Francisco January 13-15. Biotech Showcase 2025 Presentation Details Date: Tuesday, January 14, 2025 Time: 3:00 PM PT Venue: Hilton San Francisco Union Square Hotel, San Francisco, CASpine BioPharma, Inc. to Present at the Piper Sandler 36th Annual Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced that Chief Executive Officer Marc Viscogliosi will present at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5th at 12:30 p.m. E.T. in New York. About SB-01 For Injection SB-01 is a 7-amino acid synthetic peptide that binds to and antagonizes TGF-Beta activity. TGF-Beta is a pleiotropic cytokSpine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain
NEW YORK--(BUSINESS WIRE)--Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc Disease (DDD), today announced the completion of enrollment of its U.S. Phase 3 clinical trial of SB-01 For Injection (SB-01). The Phase 3 MODEL trial (MOderate – Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) enrolled 417 patients at 30 investigational sites across the U.S., in a two-year period. SB-01 is the first intradiscal phaSpine BioPharma, Inc. Announces Agreement with Ensol BioSciences, Inc. to Expand Indications for SB-01 For Injection
NEW YORK, July 10, 2024 /PRNewswire/ -- Spine BioPharma, Inc., a company committed to developing non-opiate, non-surgical therapies for the treatment of pain related disabilities, today announced that it has signed an agreement with Korean Company Ensol BioSciences, Inc. to expand the...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spine BioPharma
Sign Up For FreeTo access detailed company insights
Spine BioPharma is a company committed to developing non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain caused by degenerative disc disease. The company was established in 2015 and is headquartered out of New York City, NY.... Read More
